Conditions: Cardiovascular Diseases Kidney Failure, Chronic
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
The current study will allow the assessment of pharmacokinetics, pharmacodynamics, elimination rate and clearance of dabigatran etexilate during and following haemodialysis in ESRD patients.

Detailed description:

Arms:
arm 1: Capsule, oral arm 2: Capsule, oral arm 3: Capsule, oral

Interventions: intervention 1: Dabigatran etexilate intervention 2: Dabigatran etexilate intervention 3: Dabigatran etexilate
Intervention descriptions: intervention 1: 150 mg capsule intervention 2: 75 mg capsule intervention 3: 110 mg capsule

Protocol document: